Bio-Rad Laboratories Class A

BIO

Market cap $8.76B

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.

BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.

Bio-Rad Laboratories, Inc. ( BIO ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Yong Chung - Vice President of Investor Relations Jonathan DiVincenzo - President & COO Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron Research LLC Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products," stated Norman Schwartz, Bio-Rad's Chairman and CEO. "Despite ongoing challe.

Supplier of residential thermal, comfort and security solutions, Resideo Technologies, Inc. (REZI) was the top contributor in the quarter. Shares of gold mining company, Barrick Mining Corporation (B) also jumped in the quarter on strong financial results buoyed by rising gold prices. We added Arthur J. Gallagher & Co. (AJG), the world's largest insurance broker focused on middle-market clients.

Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens percentage of shares outstanding at great prices. Rayonier was an immediate contributor.

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside th.